Omeros (NASDAQ:OMER - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at D. Boral Capital in a research report issued on Friday,Benzinga reports. They presently have a $36.00 price objective on the biopharmaceutical company's stock.
A number of other analysts have also recently weighed in on OMER. HC Wainwright reaffirmed a "buy" rating and set a $9.00 target price on shares of Omeros in a research note on Friday, June 27th. Wall Street Zen cut shares of Omeros from a "hold" rating to a "sell" rating in a research note on Friday, June 27th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research note on Friday, May 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $18.00.
Check Out Our Latest Research Report on Omeros
Omeros Price Performance
Shares of NASDAQ:OMER opened at $4.12 on Friday. The company's 50 day simple moving average is $3.58 and its 200 day simple moving average is $5.82. The stock has a market capitalization of $254.45 million, a price-to-earnings ratio of -1.55 and a beta of 2.26. Omeros has a 1 year low of $2.95 and a 1 year high of $13.60.
Omeros (NASDAQ:OMER - Get Free Report) last posted its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.05). As a group, analysts anticipate that Omeros will post -3.09 EPS for the current fiscal year.
Hedge Funds Weigh In On Omeros
Hedge funds and other institutional investors have recently bought and sold shares of the company. Nomura Holdings Inc. raised its holdings in shares of Omeros by 136.2% during the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company's stock valued at $7,383,000 after purchasing an additional 430,932 shares during the period. Susquehanna Fundamental Investments LLC acquired a new position in shares of Omeros during the fourth quarter valued at about $1,488,000. Wellington Management Group LLP acquired a new position in shares of Omeros during the first quarter valued at about $1,118,000. Nuveen LLC acquired a new position in shares of Omeros during the first quarter valued at about $938,000. Finally, Brevan Howard Capital Management LP acquired a new position in shares of Omeros during the second quarter valued at about $316,000. Institutional investors and hedge funds own 48.79% of the company's stock.
About Omeros
(
Get Free Report)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access